For a better future SCM Lifescience will do its best
Drugs for atopic and acute pancreatitis to start exporting technology

Sun Uk Song, CEO of SCM Life Science, who recently returned to the forefront of management, met with a reporter on the 1st and said, "I will lead the company with a profit-generating model rather than investment," adding, "I will speed up clinical trials of major pipelines (candidate materials)." SCM Life Science is a bio-venture for developing stem cell treatments founded in 2014 by CEO Song, a professor at Inha University Medical School. Former CEO Lee Byung-gun, a professional manager who served as CEO of GC Green Cross and Chong Kun Dang, recently stepped down after leading for more than two years, and founder Song took the helm again. 

CEO Song said, "We will focus on the company's 'root' atopic dermatitis, acute pancreatitis, and pipelines for treating Chronic Graft-versus-Host Disease.". It is a pipeline that has been promoted since before the professional management system. "Concentrating" means push ahead with technology transfer. CEO Song said, "We will try to transfer technology more aggressively in the second half of next year when the results of phase 2 clinical trials for major pipelines are released."


Atopic dermatitis is typical. 90% of patients have been registered and the administration will be completed by the end of the year. After six months of follow-up, clinical results will be released in the second half of next year. CEO Song said, "We will also apply for phase 2 clinical trials of the U.S. Food and Drug Administration (FDA) in the middle of next year," adding, "It will have a positive impact on the promotion of technology transfer.". Handok, which received technology transfer, will take charge of the third phase of clinical trials in Korea.


Acute pancreatitis in phase 2a clinical trials was registered by 91.6 percent of patients. Acute pancreatitis has a shorter observation period than atopic dermatitis, so clinical results will be released from August to September next year. This also plans to actively attempt technology transfer.

U.S. clinical trials are also under consideration. However, the rare disease, GvHD, requires time. Since the follow-up period is one year, the results of phase 2 clinical trials will not be released until the second half of 2023.


COIMUNE's listing on the NASDAQ market is scheduled to be earlier than originally planned 2023.

CEO Song said, "After attracting funds through Series B investment by March next year, we plan to push for listing on the NASDAQ market immediately that year.". It also signed a cooperative contract with the U.S. Memory-Lon Kettering Cancer Center last month to apply COIMUNE's homogeneous chimeric antigen receptor cytokine-induced killer cell (CAR-CIK) technology to solid cancer treatment.